Fusion Antibodies plc (AIM:FAB)

Fusion Antibodies Income Statement

Financials in millions GBP. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	1.97	1.14	2.9	4.8	4.17
Revenue Growth (YoY)	72.97%	-60.84%	-39.55%	15.22%	6.93%
Cost of Revenue	1.54	1.18	2.33	2.33	2.14
Gross Profit	0.43	-0.05	0.57	2.47	2.02
Selling, General & Admin	2.05	2	3.13	3.03	2.74
Other Operating Expenses	-	-0.01	-0.01	-0.03	-0.19
Operating Expenses	2.16	2.23	3.47	3.79	3.27
Operating Income	-1.73	-2.27	-2.89	-1.33	-1.25
Interest Expense	-0	-0.01	-0	-0.01	-0.02
Interest & Investment Income	0.01	0	0	0	0
Currency Exchange Gain (Loss)	-0.05	-0.02	0.04	-	-
EBT Excluding Unusual Items	-1.78	-2.29	-2.86	-1.33	-1.26
Pretax Income	-1.78	-2.29	-2.86	-1.33	-1.26
Income Tax Expense	-0.06	-0.06	-0.26	-0.13	1.64
Net Income	-1.71	-2.23	-2.6	-1.2	-2.9
Net Income to Common	-1.71	-2.23	-2.6	-1.2	-2.9
Shares Outstanding (Basic)	96	56	26	26	25
Shares Outstanding (Diluted)	96	56	26	26	25
Shares Change (YoY)	72.58%	113.55%	0.27%	1.91%	15.24%
EPS (Basic)	-0.02	-0.04	-0.10	-0.05	-0.11
EPS (Diluted)	-0.02	-0.04	-0.10	-0.05	-0.11
Free Cash Flow	-1.37	-1.77	-1.87	-0.59	-1.5
Free Cash Flow Per Share	-0.01	-0.03	-0.07	-0.02	-0.06
Gross Margin	21.88%	-3.96%	19.79%	51.39%	48.59%
Operating Margin	-87.84%	-200.00%	-99.76%	-27.61%	-29.99%
Profit Margin	-87.18%	-195.95%	-89.49%	-25.00%	-69.60%
Free Cash Flow Margin	-69.92%	-155.90%	-64.39%	-12.25%	-36.04%
EBITDA	-1.62	-2.05	-2.55	-0.65	-0.61
EBITDA Margin	-82.65%	-180.81%	-87.80%	-13.48%	-14.60%
D&A For EBITDA	0.1	0.22	0.35	0.68	0.64
EBIT	-1.73	-2.27	-2.89	-1.33	-1.25
EBIT Margin	-87.84%	-200.00%	-99.76%	-27.61%	-29.99%

Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.